Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19

SHI Tong-fan; ZHOU Gu-cheng; ZHANG Li-ying; NIU Fan; KE Yi-cheng; ZHOU Ting; WANG Qing-sheng; JIN Xiao-jie; LIU Dong-ling; WEI Ben-jun; ZHANG Wei-qiang; ZHANG Zhi-ming; LIU Yong-qi

doi:10.13422/j.cnki.syfjx.20201704

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19

更新时间：2023-07-12

- Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 16, Pages: 26-31(2020)
- 作者机构：
  
  1.甘肃中医药大学，甘肃省高校重大疾病分子医学与中医药防治研究重点实验室，敦煌医学与转化省部共建教育部重点实验室，兰州 730000
  2.甘肃中医药大学附属医院，兰州 730000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201704
  CLC： R2-0;R22;R287
- Published Online：10 June 2020，
  
  Published：20 August 2020
- 稿件说明：
移动端阅览
史桐凡,周谷城,张利英等.宣肺化浊加减方治疗新型冠状病毒肺炎40例临床疗效观察[J].中国实验方剂学杂志,2020,26(16):26-31.

SHI Tong-fan,ZHOU Gu-cheng,ZHANG Li-ying,et al.Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):26-31.
史桐凡,周谷城,张利英等.宣肺化浊加减方治疗新型冠状病毒肺炎40例临床疗效观察[J].中国实验方剂学杂志,2020,26(16):26-31. DOI： 10.13422/j.cnki.syfjx.20201704.

SHI Tong-fan,ZHOU Gu-cheng,ZHANG Li-ying,et al.Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):26-31. DOI： 10.13422/j.cnki.syfjx.20201704.

摘要

目的

评价使用宣肺化浊加减方治疗新型冠状病毒肺炎（COVID-19）的临床疗效。

方法

选取40例确诊为COVID-19且用宣肺化浊加减方治疗的患者，观察患者在用宣肺化浊方前后体温，临床症状，计算机体层摄影（CT），血常规，生化指标等方面的变化情况。

结果

40例患者中男15例，女25例，男女比例为1∶1.7，年龄20~94岁，平均（43.9±16.3）岁，病程8~23 d，平均（14±4.4） d。与用药前比较，患者咳嗽、发热、咳痰、腹泻、食欲不振和乏力等临床症状皆有好转（

0.05）；用药前患者中医证型主要为寒湿郁肺（57.5%）和寒湿犯肺（42.5%），舌苔主要为白腻苔（52.9%）；经宣肺化浊方辅助治疗后患者退热时间为（2.48±2.56） d；患者患者白细胞总数（WBC），淋巴细胞百分比（LYM%），中性粒细胞百分比（NEUT%），淋巴细胞绝对值（LYM#），C反应蛋白（CRP），红细胞沉降率（ESR），总胆红素（TBIL），天门冬氨酸氨基转移酶与丙氨酸氨基转移酶比值（AST/ALT）和乳酸脱氢酶（LDH）等指标较用药前基本恢复至正常范围（

0.05）；经宣肺化浊加减方辅助治疗后，咽试子病毒核酸检测3次阴性，肺部CT示感染病灶已吸收，40例患者均符合出院标准已全部治愈出院，治愈率为100%，至今未有发生核酸检测转阳者复发病例；患者用药后症状与临床指标积分为（1.62±1.90），较用药前积分（7.65±4.08）明显降低（

0.05）。

结论

宣肺化浊加减方辅助治疗新冠肺炎可以降低体温、促进肺部炎症吸收、改善发烧、咳嗽等临床症状。

Abstract

Objective

To evaluate the clinical efficacy of Xuanfei Huazhuo prescription in the treatment of coronavirus disease-2019 (COVID-19).

Method

A total of 40 patients with COVID-19 were selected and treated with Xuanfei Huazhuo prescription. The changes of body temperature

clinical symptoms

computed tomography (CT)

blood routine and biochemical indexes were observed before and after treatment.

Result

The 40 patients included 15 males and 25 females

with a male to female ratio of 1∶1.7. They were aged between 20-94 years old

with the average age of （43.9±16.3） years old. The course of disease was 8-23 days

with the average of （14±4.4） days. Compared with before administration

the patients' clinical symptoms

such as cough

fever

sputum

diarrhea

loss of appetite and fatigue

were all improved (

0.05). Before treatment the traditional Chinese medicine (TCM) syndromes of patients were mainly cold dampness lung (57.5%) and cold dampness Lung (42.5%)

and the tongue coating was mainly white greasy coating (52.9%). After adjuvant treatment with Xuanfei Huazhuo prescription

the fever removal time was (2.48±2.56) days; white blood cell (WBC)

lymphocyte percentage (LYM%)

neutrophil percentage (NEUT%)

absolute value of lymphocytes (LYM #) indexes of C-reactive protein (CRP)

erythrocyte sedimentation rate (ESR)

total bilirubin (TBIL)

ratio of glutamic oxaloacetic transaminase to glutamic pyruvic transaminase (AST/ALT) and lactate dehydrogenase (LDH) were basically restored to the normal range (

0.05) compared with before administration. After adjuvant treatment with Xuanfei Huazhuo prescription

the results of three pharyngeal test virus nucleic acid tests were negative

and the lung CT showed that infected lesions were absorbed and all met the discharge criteria. All 40 patients met the discharge criteria and were all cured and discharged

with a cure rate of 100%. There has been no case of recurrence with a positive result of nucleic acid detection so far. The score of symptom and clinical index of patients after administration was （1.62±1.90）

which was significantly lower than that before administration (7.65±4.08

0.05).

Conclusion

In the adjuvant treatment of COVID-19

Xuanfei Huazhuo prescription can reduce body temperature

promote the absorption of pulmonary inflammation

and improve clinical symptoms

such as fever and cough.

关键词

Keywords

references

蔡秋杰 , 张华敏 , 王乐 , 等 . 论寒疫与新型冠状病毒肺炎（COVID-19）防治 [J]. 中医药信息 , 2020 , doi: 10.19656/j.cnki.1002-2406.200030 http://dx.doi.org/10.19656/j.cnki.1002-2406.200030 .

冯芮琪 , 路童 , 战丽彬 . “三因制宜”理论辨治新型冠状病毒肺炎探析 [J]. 中华中医药学刊 , 2020 , doi: 10.13193/j.issn.1673-7717.2020.04.004 http://dx.doi.org/10.13193/j.issn.1673-7717.2020.04.004 .

魏本君 , 王庆胜 , 雍文兴 , 等 . 甘肃新型冠状病毒肺炎特征及中医治疗 [J]. 中国中医药信息杂志 , 2020 , doi: 11.3519.R.20200225.1740.002 http://dx.doi.org/11.3519.R.20200225.1740.002 .

王鑫 , 张志明 , 王功臣 , 等 . “甘肃方剂”在新型冠状病毒肺炎防治中的应用策略分析 [J]. 中国实验方剂学杂志， 2020 ， 26 （ 16 ）: 21 - 25 .

甘肃省卫生健康委员会 . 有效防治新冠肺炎“甘肃方剂” [EB/OL]. https://new.qq.com/omn/20200216/20200216A04FZ100.html https://new.qq.com/omn/20200216/20200216A04FZ100.html , 2020-02-15 / 2020-02-26 .

国家卫生健康委员会 . 关于印发新型冠状病毒肺炎诊疗方案(试行第三版)的通知 [EB/OL]. http://www.nhc.gov.cn/xcs/yqfkdt/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml http://www.nhc.gov.cn/xcs/yqfkdt/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml , 2020-01-22 / 2020-02-26 .

国家卫生健康委员会 . 关于印发新型冠状病毒肺炎诊疗方案(试行第四版)的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml , 2020-01-27 / 2020-02-26 .

国家卫生健康委员会 . 关于印发新型冠状病毒肺炎诊疗方案(试行第五版修正版)的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml , 2020-02-08 / 2020-02-26 .

国家卫生健康委员会 . 关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml , 2020-02-18 / 2020-02-26 .

王辉 , 邱建强 , 乔黎焱 , 等 . 新型冠状病毒肺炎中医论治初探 [J]. 陕西中医 , 2020 , 41 ( 3 ): 285 - 286,397 .

刘秋江 , 陈垚 , 赵海方 , 等 . 新型冠状病毒肺炎的辨证施治 [J]. 中华中医药学刊 , 2020 , doi: 21.1546.R.20200320.1325.002 http://dx.doi.org/21.1546.R.20200320.1325.002 .

任伟钰 , 苏敬 , 刘永琦 , 等 . 全国各省区中医药治疗新型冠状病毒肺炎（COVID-19）的诊疗方案分析 [J]. 中草药 , 2020 , 51 ( 5 ): 1139 - 1146 .

闵瑞 , 刘洁 , 代喆 , 等 . 新型冠状病毒肺炎发病机制及临床研究进展 [J]. 中华医院感染学杂志 , 2020 , doi： 11.3456.R.20200304.1653.002 http://dx.doi.org/11.3456.R.20200304.1653.002 .

王艳宏 , 王秋红 , 夏永刚 , 等 . 麻黄化学拆分组分的性味药理学评价——麻黄化学拆分组分“辛温”发汗，利水作用的实验研究 [J]. 中国中医药科技 , 2011 , 18 ( 6 ): 489 - 491 .

宋建平 , 张立伟 . 连翘木脂素研究进展 [J]. 文山学院学报 , 2019 , 32 ( 6 ): 28 - 34 .

刘晓君 , 杨洁芳 . 黄芩苷对急、慢性肝损伤模型鼠的保护作用 [J]. 中国药房 , 2014 , 25 ( 15 ): 1374 - 1376 .

余晶 , 覃洁萍 , 邱华 , 等 . 黄芩苷对抗牛磺酸脱氧胆酸诱导肝细胞损伤的实验研究 [J]. 广西中医药大学学报 , 2014 , 17 ( 2 ): 3 - 7 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Material Basis of Xuanfei Huazhuo Prescription in Treatment of COVID-19 by Multi-target Molecular Docking

Efficacy of Shexiang Tongxin Dropping Pills in Treatment of Coronary Slow Flow and Its Effect on Inflammatory Factors

Efficacy and Safety of Lianhua Qingwen Preparation in Treatment of Community-acquired Pneumonia：A Systematic Review and Meta-analysis

Clinical Observation and Research on Prevention and Treatment of Epilepsy Complicated with Cognitive Impairment by Quyu Dingxian Zhengtong Mixture for Dispelling Stasis and Resolving Phlegm

Clinical Efficacy of Tongxie Yaofang on Diarrhea-predominant Irritable Bowel Syndrome （IBS-D） Patients with Liver Depression and Spleen Deficiency

Related Author

FENG Cai-qin

ZHANG Zhi-ming

ZHANG Yue-mei

WANG Yan-ru

YONG Wen-xing

TAI An-ning

LI Dan-gui

JIN Xiao-jie

Related Institution

The First Hospital of Lanzhou University

Dunhuang Key Laboratory of Medicine and Transformation under Ministry of Education,Gansu Provincial Key Laboratory for Molecular Medicine of Major Diseases and Prevention and Treatment with Traditional Chinese Medicine for Colleges and Universities,Gansu University of Chinese Medicine

Dongzhimen Hospital， Beijing University of Chinese Medicine

The Second Hospital of Hebei Medical University

Beijing Hospital of Traditional Chinese Medicine， Capital Medical University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰